NewsSTERNA BIOLOGICALS
_____
2019
Company news 2019
-
sterna biologicals to attend international partnering and investor conferences in November
Marburg, Germany, November 07, 2019
Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announced that the Company will participate and present at the following partnering and investor conferences in November: -
sterna biologicals invited to present at the GOODWIN - SOLEBURY TROUT - NASDAQ european biotech investor day 2019
Marburg, Germany, 25 July 2019
- sterna biologicals selected as one of a group of top-tier European biotech companies to present at the European Biotech Investor Day on August 1, 2019 in New York City
- CEO Christian Pangratz to discuss the Company’s robust development progress and next phase of growth fueled by sterna’s first-in-class DNAzyme hgd40 in Phase 2 development for asthma and ulcerative colitis
-
sterna biologicals strengthens management team to progress towards phase IIB development
Marburg, Germany, 08 July 2019
- Industry veteran Dr. Marion Wencker strengthens sterna’s management team as consulting CMO
- Financial expert Dr. Thomas Klaue recently joined sterna as consulting CFO
sterna biologicals GmbH & Co. KG (Sterna), an innovative clinical-stage immunology company developing novel biological treatments for chronic inflammatory diseases, announced today that the Company has recently appointed Dr. Marion Wencker as consulting Chief Medical Officer and Dr. Thomas Klaue as consulting Chief Financial Officer.